Autologous CD34+ Cell Therapy for Myocardial Infarct Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for preventing long-term adverse consequences of vascular insufficiency, particularly after myocardial infarction, as they fail to effectively address the expansion of the myocardial infarct area and progression to heart failure.
Innovation Solution
Administration of a potent dose of nonexpanded, isolated autologous mononuclear cells enriched for CD34+ cells, which contain a subpopulation of potent CD34+/CXCR-4+ cells with CXCR-4-mediated chemotactic activity, to treat vascular insufficiency early or late after myocardial infarction, reducing major adverse cardiac events and improving myocardial perfusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat vascular insufficiency after myocardial infarction, then treatment is provided, but they fail to effectively prevent expansion of the myocardial infarct area and progression to heart failure
Solution Approach 1:
The patent utilizes the patient's own autologous mononuclear cells enriched for CD34+ cells to treat the vascular insufficiency. The cells are harvested from the patient, processed to enrich CD34+ cells, and reinfused to promote endogenous repair mechanisms, allowing the body to heal itself rather than relying on external therapies that have proven ineffective
Solution Approach 2:
The patent changes the therapeutic parameter from conventional medications and procedures to a cellular therapy involving autologous mononuclear cells enriched for CD34+ cells. This parameter change represents a fundamental shift from pharmacological/mechanical intervention to biological/regenerative intervention, aiming to overcome the limitations of current therapies
2Reliability
If a potent dose of autologous mononuclear cells enriched for CD34+ cells is administered, then neoangiogenesis is promoted and cardiac function is preserved, but the treatment complexity and procedural steps increase
Solution Approach 1:
The patent divides the therapeutic intervention into distinct segments: (1) harvesting autologous mononuclear cells, (2) processing to enrich CD34+ cells, (3) formulating the cell product, and (4) reinfusing the enriched cells. This segmentation allows each step to be optimized and controlled separately, managing the overall complexity through structured procedural breakdown
Solution Approach 2:
The patent introduces an intermediary processing step that enriches autologous mononuclear cells for CD34+ cells before reinfusion. This intermediary step acts as a mediator between the initial cell harvest and the final therapeutic administration, concentrating the most beneficial cell population to enhance therapeutic efficacy while managing complexity through focused processing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces premature death, recurrent myocardial infarction, congestive heart failure, and arrhythmias by promoting neoangiogenesis and preserving cardiac function, thereby limiting infarct expansion and ventricular remodeling.
Implementation Method 1
a subpopulation of potent CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity
Data Source
AI summary
The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.